THERAPY DOSSIER · th-69eb87af1608

Erlotinib; rapamycin (sirolimus) as a second active arm

Drug · Epidermal growth factor receptor erbB1 (EGFR) inhibitor (INHIBITOR; direct interaction; disease efficacy). ATC L01EB02.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Epidermal growth factor receptor erbB1 (EGFR) inhibitor (INHIBITOR; direct interaction; disease efficacy). ATC L01EB02.
Target: CHEMBL203 (epidermal growth factor receptor erbB1, EGFR)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 2004
Development stage: Not recorded
ChEMBL record: CHEMBL553 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Erlotinib; Erlotinib hydrochloride; Tarceva; OSI-774; CP-358,774; R-1415; RG-1415; Ro-508231
Note: Not recorded

Clinical trials 9

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00268684 ↗PHASE3unknown

WBRT and SRS Alone vs With Temozolomide or Erlotinib in NSCLC With Brain Metastases

Non-Small-Cell Lung Carcinoma · Neoplasm Metastasis

Enrolment: 381 · Results not recorded

NCT01377376 ↗PHASE3terminated

ARQ 197 Plus Erlotinib vs Placebo Plus Erlotinib in EGFR Wild-type Non-Squamous NSCLC

Non-small-cell Lung Cancer

Enrolment not recorded · Results not recorded

NCT00059852 ↗PHASE2completed

OSI-774 (Tarceva) and Gemcitabine in Metastatic Breast Cancer

Breast Cancer

Enrolment: 61 · Results not recorded

NCT00294762 ↗PHASE2completed

Tarceva Alone or Intercalated With Chemotherapy in Newly Diagnosed Advanced NSCLC

Non-Small-Cell Lung Carcinoma

Enrolment: 143 · Results not recorded

NCT00055913 ↗PHASE1/PHASE2completed

Bevacizumab With OSI-774 in Recurrent or Metastatic Head and Neck Cancer

Recurrent/Stage IV Head and Neck Squamous Cell Carcinoma

Enrolment: 58 · Results not recorded

NCT06483555 ↗PHASE1/PHASE2recruiting

Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) in Basal-like Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

Enrolment: 104 · Results not recorded

NCT01911507 ↗PHASE1completed

INC280 Plus Erlotinib in c-Met Expressing Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

Enrolment: 35 · Results not recorded

NCT01284335 ↗PHASE1terminated

LY573636-sodium With Gemcitabine, Docetaxel, Temozolomide, Cisplatin or Erlotinib in Advanced Solid Tumours

Advanced Solid Tumors

Enrolment: 234 · Results not recorded

NCT00975767 ↗PHASE1terminated

MGCD265 With Erlotinib or Docetaxel in Advanced Malignancies and NSCLC

Advanced Malignancies · Non-small Cell Lung Cancer

Enrolment: 126 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24445976 ↗2014Mixed findings

Oral erlotinib, but not rapamycin, causes modest acceleration of bladder and hindlimb recovery from spinal cord injury in rats.

RatSpinal cord injuryContusionSprague-DawleyFemaleOral (erlotinib)Started directly after contusion injury, during the acute phase

Model: Spinal cord contusion injury

Erlotinib accelerated locomotor recovery and slightly improved bladder recovery but produced no long-term locomotor improvement. Rapamycin improved neither locomotor nor bladder recovery. Neither regimen improved long-term functional outcome.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…